Over 965,000 percutaneous coronary interventions are performed annually in the United States alone. Yet despite extraordinary advances in stent technology, pharmacology, and operator skill, three categories of lesions continue to defeat even the most experienced hands: chronic total occlusions, bifurcation lesions, and severely calcified or tortuous vessels. The common thread is not complexity — it is the fundamental absence of forward-looking visualization at the wire tip. This article examines the clinical and market evidence for why a new imaging paradigm — the Scanning Fiber Endoscope (SFE) — is poised to become the most consequential tool introduced into the cath lab since the drug-eluting stent.

THE MARKET CONTEXT: A BILLION-DOLLAR PROBLEM GROWING EVERY YEAR

Cardiovascular disease remains the leading cause of death worldwide. In the United States alone, someone suffers a heart attack every 40 seconds — and cardiac disease accounts for one in five deaths annually. The procedural response to this epidemic has built one of medicine's largest and fastest-growing device markets.

The intravascular imaging segment — the market most directly relevant to procedure guidance — reached approximately $1.12 billion globally in 2025 and is projected to exceed $1.59 billion by 2030, growing at a compound annual rate of 6.8%. North America commands roughly 45% of that market, dominated by IVUS technology, which holds approximately 58% of the imaging segment, followed by OCT.

Source: Mordor Intelligence, Intravascular Ultrasound Devices Market Report, 2025; Fortune Business Insights, Interventional Cardiology Devices Market, 2024

Yet the most striking market dynamic is not the growth of the existing market — it is the enormous clinical gap that existing tools fail to address. IVUS and OCT, despite being sophisticated and evidence-backed technologies, share a fundamental architectural limitation: they look sideways. They image the vessel wall around the catheter. Neither looks forward. Neither sees what lies ahead of the wire.

That limitation, as will be demonstrated, is the single greatest unmet need in complex coronary intervention. And the market for the solution does not yet have a line item.

THE THREE PROBLEMS THAT CURRENT TECHNOLOGY CANNOT SOLVE

Before examining the specific clinical gaps, it is worth establishing the shared anatomy of failure across all three problem categories. The interventionalist who faces a CTO, a complex bifurcation, or a severely calcified vessel is confronted not merely with an anatomical challenge — they are confronted with an information problem. They do not know, in real time, what they are about to enter. IVUS and OCT tell the story of where you have been. They are retrospective imaging tools operating in a prospective environment. Every guidewire crossing, every balloon inflation, every stent deployment involves a moment of committed action taken without visual confirmation of what comes next.

The limitation is not the operator's skill. It is the fundamental directionality of every imaging tool currently available.

PROBLEM #1: CHRONIC TOTAL OCCLUSIONS — NAVIGATING IN COMPLETE DARKNESS

Chronic total occlusions are defined as coronary artery blockages with no antegrade blood flow (TIMI 0) for a duration of at least three months. They are among the most common and most challenging lesions encountered in interventional cardiology.

What We Know About the Scope of the Problem

CTOs are identified in 18.4% to 52% of patients with coronary artery disease (CAD) who undergo coronary angiography. The procedural success rate at expert, high-volume CTO centers has improved significantly — the PROGRESS-CTO registry, encompassing over 10,000 procedures across 40 centers, reported an overall technical success rate of 86%, with improvement from 81.6% in 2016 to 88.1% by 2021. For dedicated CTO operators, success rates exceeding 90% are documented.

Source: PROGRESS-CTO Registry, SCAI 2022 Scientific Sessions; Outcomes of CTO PCI in a Non-Surgical Centre, Interventional Cardiology 2024

However, the picture shifts dramatically outside of specialized centers. Analysis of community practice reveals success rates of 50% or lower when CTOs are attempted by general interventionalists without subspecialty CTO training. And the consequences of failure are not merely procedural disappointment.

The Cost of Getting It Wrong

A 2024 study published in the European Journal of Cardiovascular Medicine, analyzing 212 consecutive CTO PCI procedures at a single tertiary center, found that failed interventions were associated with substantially higher rates of coronary dissection (34% vs. 5%, p<0.0001) and coronary perforation (17% vs. 2.5%, p<0.0001) compared to successful procedures. Cardiac tamponade requiring urgent intervention occurred in 9.4% of failed cases versus 2.5% of successful ones. It is important to note that these figures reflect complications specifically within failed procedures at a single center; the PROGRESS-CTO registry — encompassing 10,249 procedures across 40 international centers — reports overall major periprocedural complication rates of approximately 2.1%, rising to 6.6% in high-risk cases as defined by the PROGRESS-CTO risk score.

The single-center figures and the registry data are not contradictory: the registry captures all-comer CTO attempts including successful ones, while the single-center analysis isolates the complication profile of failed procedures specifically. Both datasets point to the same clinical reality — failure carries a substantially higher complication burden than success.

Source: Technical Success and In-Hospital Outcomes in CTO PCI, European Journal of Cardiovascular Medicine, October 2024

These are not statistical abstractions. Coronary perforation during a CTO attempt can require emergent pericardiocentesis or emergency surgery. The procedural radiation exposure from a 90-minute CTO attempt is substantial. And for the patient who waits months for an appropriately timed procedure, a failed CTO attempt can mean re-referral, re-staging, and a second high-risk intervention.

The Root Cause: The Wire Cannot See Where It Is Going

The primary driver of CTO failure is guidewire crossing difficulty. The morphology of total occlusive plaque — dense fibrous tissue, calcium deposits, and foam cell infiltration — means the operator is attempting to navigate a guidewire through material with unpredictable internal architecture, relying on inference from angiographic projections that show only the silhouette of what lies upstream and downstream.

Multiple CTO difficulty scoring systems — the J-CTO score, the PROGRESS-CTO score, and the CASTLE score — use variables like calcification, tortuosity, lesion length, blunt entry stump, and proximal cap ambiguity precisely because these are the features that make the internal architecture of an occlusion hardest to anticipate. The inability to see forward along the wire path is not incidental to CTO difficulty. It is definitional.

Source: Predicting Successful CTO Recanalization, JACC Cardiovascular Interventions, 2023; J-CTO Score validation literature

What IVUS and OCT offer: Both technologies can confirm wire position after crossing — verifying true versus false lumen, assessing stent expansion, evaluating edge dissection. These are genuine and documented benefits. IVUS-guided CTO PCI has been associated with improved clinical outcomes compared to angiography-guided approaches in multiple studies.

What they cannot provide: Neither IVUS nor OCT can show the operator what is immediately ahead of the guidewire during crossing. Both technologies image the vessel wall radially around the catheter — not forward along the axis of travel. The moment of crossing, which is the most consequential and highest-risk phase of CTO PCI, remains visually unguided.

PROBLEM #2: BIFURCATION PCI — IRREVERSIBLE DECISIONS ON INCOMPLETE INFORMATION

Bifurcation lesions — coronary stenoses occurring at or near a branch point — represent approximately 20-25% of all percutaneous coronary interventions. They are the second most common complex lesion subset in interventional cardiology, and unlike CTOs, they are encountered routinely by every interventionalist, not just specialists.

The Clinical Stakes of Bifurcation Geometry

Analysis of the National Inpatient Sample database covering 9.79 million PCI procedures from 2016 to 2020 found that patients undergoing bifurcation PCI had a significantly higher in-hospital mortality rate (3.79%) compared to those with non-bifurcation lesions (2.56%), representing a 50% increase in mortality odds (OR 1.50, CI 1.34-1.68, p<0.001). Complication rates across multiple endpoints were substantially elevated.

Source: PCI Involving Coronary Bifurcation is Associated with Higher Mortality, PMC 2024; National Inpatient Sample Database 2016-2020

The most feared acute complication is side branch occlusion (SBO): the closure of a major branch vessel following main vessel stenting. According to data from the COBIS II registry — one of the largest bifurcation PCI datasets ever assembled — SBO occurred in 8.4% of 2,227 bifurcation procedures. The PROGRESS-BIFURCATION registry reported incidence as high as 13%, and a 2025 retrospective analysis of 553 LAD bifurcation cases confirmed an SBO rate consistent with 7.4-16.7% across the published literature.

Source: COBIS II Registry, JACC 2013; V-RESOLVE Trial; Frontiers in Cardiovascular Medicine, 2025

SBO is not a minor complication. It can result in perioperative myocardial infarction, stent thrombosis, and a cascade of ischemic injury — outcomes with both immediate morbidity and long-term prognostic implications. Periprocedural MI is independently associated with increased short- and long-term all-cause mortality in PCI populations.

The Geometry Problem That Current Imaging Does Not Solve

The fundamental challenge in bifurcation PCI is predicting, before the stent is deployed, what will happen to the side branch ostium when the main vessel is dilated. The anatomical variables that determine this — carina angle, plaque distribution at the ostium, side branch lesion length, proximal-to-distal vessel diameter ratios — are three-dimensional spatial relationships that two-dimensional angiography systematically underestimates.

OCT and IVUS substantially improve upon angiography. Both provide cross-sectional vessel wall information unavailable on fluoroscopy. A 2023 New England Journal of Medicine randomized controlled trial (NEJM 2023;389:1477-1487) demonstrated that OCT-guided PCI in complex bifurcation lesions was associated with improved outcomes compared to angiography guidance. A network meta-analysis published in JACC: Cardiovascular Interventions in January 2026, encompassing 13,751 patients across 17 randomized controlled trials, confirmed that both OCT (RR 0.63, p<0.001) and IVUS (RR 0.67, p<0.001) demonstrated superiority over angiography-guided PCI in reducing MACE across complex lesion subsets including bifurcations.

Source: NEJM 2023;389:1477-1487; JACC Cardiovascular Interventions Network Meta-Analysis, January 2026

What remains unsolved: Even with OCT or IVUS guidance, the operator cannot visualize the side branch ostium and its three-dimensional relationship to the stent position in real time, from the perspective of the wire navigating the bifurcation. Both modalities provide cross-sectional retrospective information. The moment of wire passage into a jailed side branch — the moment when the stent struts are being crossed under wire tension — is still performed without forward visualization. The operator sees the geometry of what has occurred, not what is about to occur.

PROBLEM #3: CALCIFIED AND TORTUOUS VESSELS — WHERE EVERY MILLIMETER IS A COMMITMENT

Coronary artery calcification is not a niche clinical scenario. It is an epidemiological reality of an aging, diabetic, and renally impaired population that increasingly presents to cath labs with lesion complexity that would not have been attempted percutaneously a decade ago. The CHIP — Complex, High-Risk, and Indicated Patient — population is growing.

Severely calcified lesions create procedural risk in multiple dimensions simultaneously. Wire escalation through calcified segments carries the risk of perforation. Balloon inflation in a calcified vessel risks uncontrolled dissection. Stent deployment in inadequately prepared calcified tissue leads to under-expansion, edge dissection, and the well-documented long-term consequences of malapposition. Tortuous vessels — angulated, helical coronary anatomy — create parallel risks: catheter-induced spasm, wire-tip perforation at the outer curve of a tight bend, and loss of wire position during device exchanges.

The Evidence Base for Imaging-Guided PCI in Complex Lesions

The overall clinical evidence for intravascular imaging guidance over angiography alone in complex PCI is now definitive. A landmark 2024 Lancet network meta-analysis (Stone et al., Lancet 2024;403:824-837) analyzed 22 randomized controlled trials encompassing 15,964 patients and reported the following outcomes in imaging-guided versus angiography-guided PCI:

The RENOVATE-COMPLEX-PCI trial, published in the New England Journal of Medicine in 2023 and updated in 2024 (JAMA Cardiology 2024;9:466-474), randomized 1,639 patients with complex coronary disease to intravascular imaging-guided versus angiography-guided PCI. Target vessel failure — the composite of cardiac death, target vessel MI, and clinically driven revascularization — was 7.7% in the imaging group versus 12.3% in the angiography-alone group (p<0.001).

Source: Lee JM et al., RENOVATE-COMPLEX-PCI, NEJM 2023;388:1668-1679; Stone GW et al., Lancet 2024;403:824-837

Despite this level of evidence, intravascular imaging remains dramatically underutilized in routine PCI practice. OCT — the more recently validated modality — is currently used in only approximately 3% of PCI procedures performed in the United States. IVUS utilization, while higher, also falls far short of guideline recommendations for complex lesion subsets. The 2022 ACC/AHA/SCAI PCI guidelines have strengthened imaging guidance recommendations, and the 2025 ACC/AHA guidelines for management of acute coronary syndromes further reinforce imaging-guided PCI, but adoption has not kept pace with the evidence.

Source: Mount Sinai Newsroom, February 2024; 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline, JACC 2025

The persistent limitation: Even with maximum utilization of current imaging, the calcified vessel navigation problem is not fully solved. Wire escalation through heavily calcified, tortuous segments requires the operator to commit a wire trajectory without knowing whether the next millimeter of anatomy is a manageable curve or a perforation risk. Current imaging tells the operator what the vessel looks like after they have arrived. It does not tell them what they will encounter before they get there.

This is not a limitation of IVUS or OCT resolution — it is an architectural constraint that no amount of improvement in lateral imaging can address. The Lancet 2024 network meta-analysis (Stone et al.) confirms that even with imaging-guided PCI, residual complication risk in high-complexity lesion subsets persists, underscoring that guidance of what has already been entered is a fundamentally different problem from guidance of what is about to be entered.

THE PARADIGM SHIFT: FROM RETROSPECTIVE TO PROSPECTIVE IMAGING

Every improvement in intravascular imaging over the last three decades has followed the same architectural paradigm: improved resolution, improved tissue characterization, improved pullback speed, improved software interpretation — all of the vessel wall radially surrounding the catheter. The axis of imaging has never been the axis of intervention.

The catheter moves forward. The clinician must move forward. Every meaningful decision in complex PCI — does the wire continue or redirect? Is this the true lumen or false lumen? Will the side branch be jailed? Is calcification ahead worse than what I just passed? — is a decision made along the forward axis. And that axis has remained unlit.

IVUS and OCT show you where you have been. The Scanning Fiber Endoscope shows you where you are going.

Scanning Fiber Endoscope (SFE) technology uses a miniaturized, resonantly scanned optical fiber to generate high-resolution forward-looking imagery at the distal tip of an intravascular catheter. Unlike conventional fiber optics — which require rigid bundles or complex rotation mechanisms — the SFE platform achieves true distal scanning through a single optical fiber driven into resonant vibration by a piezoelectric actuator. The result is a compact, flexible catheter-compatible imaging system capable of visualizing tissue and structure along the direction of travel.

This is not an incremental improvement on IVUS or OCT. It is a different axis entirely. For the first time, the interventionalist gains access to imaging that answers the question that has always mattered most in complex PCI: What am I about to enter?

CLINICAL APPLICATIONS: HOW SFE CHANGES THE THREE SCENARIOS

CTO PCI: Guidewire Crossing With Visual Confirmation

In CTO intervention, SFE enables the operator to visualize the internal microarchitecture of the occlusion ahead of the guidewire tip in real time. The distinction between fibrous tissue, calcium, and adjacent soft-plaque architecture — currently inferred from angiographic and CT data taken before the patient entered the lab — becomes directly observable during the procedure. Wire perforation into the pericardial space or adventitia becomes a preventable event rather than a recognized complication.

The false lumen entry that accounts for many CTO failures becomes diagnosable at the moment of occurrence rather than after multiple wire passes have already committed the operator to an incorrect trajectory.

The asymmetry between dedicated CTO expert centers (90%+ success) and general laboratory experience (50% success) is not purely a matter of operator training — it reflects an information gap that training attempts to compensate for but cannot fully close. Forward-looking imaging attacks that gap at the source.

Bifurcation PCI: Three-Dimensional Geometry in Real Time

In bifurcation intervention, SFE allows direct visualization of the carina, side branch ostium, and the spatial geometry of the branch point before stent deployment decisions are made. The operator who cannot currently see whether a jailed wire is properly positioned for recrossing through the correct stent strut cell — a critical technical variable for bifurcation optimization — gains real-time forward visual guidance for that decision.

The implications extend to the entire procedure strategy: lesion assessment before first wire, wire positioning before balloon, stent sizing and placement decisions, and post-dilation confirmation — all currently performed with retrospective lateral imaging — gain a prospective forward dimension.

Calcified and Tortuous Vessels: Knowing Before Committing

In heavily calcified and angulated coronary anatomy, SFE addresses the fundamental driver of wire escalation complication: committing to a trajectory without knowing whether the anatomy ahead supports it. Real-time visualization of calcified deposits ahead of the wire tip allows the operator to anticipate, rather than discover, the morphology that will determine whether the next wire choice should be a workhorse, a stiff polymer-jacketed wire, or whether rotational atherectomy preparation is required before any wire escalation.

This is the difference between planning and reacting. Every perforation, every dissection, every failed wire escalation that leads to emergency salvage surgery represents a moment when the operator was reacting. Forward visualization converts that reactive moment into a planned one.

THE MARKET OPPORTUNITY: AN UNOCCUPIED SEGMENT IN A GROWING MARKET

The intravascular imaging market currently segments around two technologies: IVUS ($1.12B globally in 2025, growing at 6.8% CAGR to $1.59B by 2030) and OCT (the faster-growing segment, with projected CAGR exceeding 8%). Both markets are expanding, driven by guideline-level evidence, growing cardiovascular disease burden, and an aging global population.

Source: Mordor Intelligence, IVUS Devices Market 2025; Grand View Research, IVUS Market Report

The forward-looking imaging segment does not yet exist as a commercial market. The addressable opportunity is not a sub-segment of the current IVUS or OCT market — it is an adjacent, new market defined by the procedures and lesion subsets that current imaging cannot adequately serve. Given that CTOs, bifurcation lesions, and calcified vessels together represent a substantial and growing fraction of all PCI procedures — and that procedure volume in the United States alone is projected to exceed one million annually by 2026 — the commercial addressable market for catheter-based forward-looking imaging is not a niche.

Source: iData Research, U.S. Angioplasty Procedural Volume Analysis, 2025

The convergence of factors creating this opportunity is well-established: rising cardiovascular disease burden, increasing procedural complexity (the CHIP population growth), guideline pressure toward imaging guidance, demonstrated mortality and MACE reduction benefits, and the absence of any existing forward-looking intravascular imaging platform in commercial development with an imminent regulatory pathway.

CONCLUSION: THE QUESTION EVERY INTERVENTIONALIST WILL SOON BE ASKING

The history of intravascular imaging is the history of giving the operator progressively more information about the vessel wall surrounding the catheter. From bare angiography to IVUS to OCT, each advance has reduced uncertainty about what the catheter has already passed through. The clinical dividend — documented across thousands of randomized patients and millions of real-world procedures — is substantial: fewer stent thromboses, fewer target vessel failures, fewer deaths.

The next chapter in this history will not be written by giving the operator better views of the vessel they have already entered. It will be written by giving the operator a view of the vessel they are about to enter.

When that technology arrives in the cath lab — when an interventionalist facing a proximal cap ambiguity on a CTO can see the fibrous architecture ahead of the wire, when the bifurcation operator can visualize the carina geometry before committing to a stent position, when the operator navigating a tortuous calcified segment can see the anatomy that awaits the next wire escalation — the question will not be whether this changes practice.

The question will be: how did we ever work without it?

"Intravascular imaging guidance of PCI procedures makes a greater impact to improving our patients' lives than other routine therapies which are more widely used and reimbursed." — Dr. Gregg Stone, Columbia University Medical Center, 2024

If you are an interventionalist navigating complex coronary cases, we would welcome your perspective. Connect with us on LinkedIn or reach out directly.

REFERENCES AND CITATIONS

[1] PROGRESS-CTO Registry — SCAI 2022 Scientific Sessions. Contemporary In-Hospital Outcomes and Temporal Trends of CTO Interventions. Procedural success rate 86% overall; 88.1% by 2021.

[2] Outcomes of CTO PCI in a Non-Surgical Centre. Interventional Cardiology 2024;19:e05. Dedicated operators 90.1% vs. general operators 50.0% success.

[3] Technical Success and In-Hospital Outcomes in CTO PCI. European Journal of Cardiovascular Medicine, October 2024. Single-center retrospective study, n=212, tertiary hospital, South India. Figures reflect complications in failed vs. successful procedures specifically, not overall CTO PCI rates. Failed procedures: dissection 34% vs. 5% (p<0.0001), perforation 17% vs. 2.5% (p<0.0001), tamponade 9.4% vs. 2.5%. Cross-reference with PROGRESS-CTO Registry [Ref 1] for multi-center all-comer data: overall MACE 2.1%; risk-stratified complication rate 0.2% (low) / 2.0% (intermediate) / 6.6% (high-risk). Both datasets are consistent — failure carries a substantially higher complication burden than success.

[4] Chronic Total Occlusions: Found in 18.4-52% of CAD patients on angiography. European Journal of Cardiovascular Medicine, October 2024.

[5] J-CTO Score and CTO Difficulty Scoring. JACC Cardiovascular Interventions 2023. Scoring variables include calcification, tortuosity, blunt stump, proximal cap ambiguity.

[6] Holm NR et al. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions. N Engl J Med 2023;389:1477-1487.

[7] Hahn JY et al. Predictors and Outcomes of Side Branch Occlusion After Main Vessel Stenting: COBIS II Registry. JACC 2013;62:1654-1659. SBO occurred in 8.4% of 2,227 bifurcation lesions.

[8] Side Branch Occlusion Incidence. Frontiers in Cardiovascular Medicine, 2025. 553-patient LAD bifurcation study; SBO incidence 7.4%, consistent with published range of 7.4-16.7%.

[9] Bifurcation PCI and Inpatient Mortality. Nathan et al., PMC 2024. NIS database 2016-2020; bifurcation cohort mortality 3.79% vs. 2.56% non-bifurcation (OR 1.50, p<0.001).

[10] EuroIntervention. Percutaneous Coronary Intervention of Bifurcation Lesions. Bifurcation lesions account for approximately 20% of all PCIs.

[11] Stone GW et al. Intravascular Imaging-Guided Coronary Drug-Eluting Stent Implantation: Updated Network Meta-Analysis. Lancet 2024;403:824-837. 22 RCTs, 15,964 patients. Imaging guidance: 45% reduction in cardiac death, 25% reduction in all-cause death, 48% reduction in stent thrombosis.

[12] Lee JM et al. (RENOVATE-COMPLEX-PCI). Intravascular Imaging-Guided vs. Angiography-Guided Complex PCI. NEJM 2023;388:1668-1679. TVF 7.7% imaging vs. 12.3% angiography.

[13] JACC: Cardiovascular Interventions Network Meta-Analysis, January 2026. 17 RCTs, 13,751 patients. OCT RR 0.63, IVUS RR 0.67 vs. angiography for MACE in complex lesions (both p<0.001).

[14] Mount Sinai Newsroom, February 2024. Summary of Lancet 2024 meta-analysis. OCT used in only 3% of U.S. PCI cases.

[15] iData Research. Over 965,000 Angioplasties Performed Each Year in the United States; projected to exceed 1 million by 2026.

[16] Mordor Intelligence. Intravascular Ultrasound Devices Market Report, 2025. IVUS market $1.12B in 2025, projected $1.59B by 2030 at 6.8% CAGR.

[17] Grand View Research. IVUS Devices Market 2024-2030. Global IVUS market $807.8M in 2023, projected $1.147B by 2030.

[18] Fortune Business Insights. Interventional Cardiology Devices Market 2025-2032. Global market $16.69B in 2024, projected $29.32B by 2032 at 7.3% CAGR.

[19] Future Market Insights. Intravascular Imaging Market 2025-2035. Market $430.8M in 2025, projected $701.7M by 2035 at 5.0% CAGR.

[20] Rao SV et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for Management of Patients with Acute Coronary Syndromes. JACC 2025.

[21] Dr. Gregg Stone, Columbia University Medical Center. Quote from Mount Sinai press release, February 2024, regarding Lancet imaging meta-analysis findings.